- Home
- » Tags
- » Dihydrotetrabenazine
Top View
- Long-Term Methamphetamine Administration in the Vervet Monkey Models Aspects of a Human Exposure: Brain Neurotoxicity and Behavioral Profiles
- Brain Sciences ISSN 2076-3425 Review Functional and Structural Brain Changes Associated with Methamphetamine Abuse
- Neuroprotection Or Neurotoxicity of Illicit Drugs on Parkinson's Disease
- Predicting Drug Responses by Propagating Interactions Through Text-Enhanced Drug-Gene Networks
- Evaluation of the Superselective Radioligand [ I]PE2I for Imaging of the Dopamine Transporter in SPECT
- Escalating Dose Methamphetamine Pretreatment Alters the Behavioral and Neurochemical Profiles Associated with Exposure to a High-Dose Methamphetamine Binge
- 209241Orig1s000
- (VMAT2) Radioligand Binding in MPTP-Treated Mice
- The Biochemical and Cellular Basis for Nutraceutical Strategies to Attenuate Neurodegeneration in Parkinson's Disease
- Download Product Insert (PDF)
- NOVUM PHARMACEUTICAL RESEARCH SERVICES INC SMALL MOLECULES New / Sr
- Oxidative Modification of Vesicular Transporters in an Animal Model Of
- The Role of Dopamine Transporter Imaging in Movement Disorders
- 3,4-Methylenedioxypyrovalerone (MDPV)
- [11C]DTBZ Positron Emission Tomography in Clinically Uncertain Parkinsonism: Experience of a Single Tertiary Center
- AUSTEDO (Deutetrabenazine) RATIONALE for INCLUSION IN
- Pancreatic Imaging with 11C- Dihydrotetrabenazine PET: a Perspective
- Pdf/Pubs/2017-Cdc-Drug-Surveillance- Report.Pdf, Centers for Disease Control and Prevention, U.S
- Pancreatic Imaging with 11C- Dihydrotetrabenazine PET: a Perspective
- 11C-Dihydrotetrabenazine B-Cell Imaging
- WO 2014/047167 Al 27 March 2014 (27.03.2014) P O P C T
- Qps Drug Assay List
- Dopamine Transporter Imaging in Neurodegeneration
- The Dopamine Hypothesis of Bipolar Affective Disorder: the State of the Art and Implications for Treatment
- Characterization of Influx Transporters in the Blood-Brain Barrier: Implications for Drug Delivery
- Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: an Update
- Monday, December 4, 2006 Panel Session Co-Morbid Pain
- WO 2015/120110 A2 13 August 2015 (13.08.2015) P O P C T
- 1 New MRI, 18F-DOPA and 11C-(+)-Α-Dihydrotetrabenazine
- View Berlin, Germany Late-Breaking Abstracts
- (12) Patent Application Publication (10) Pub. No.: US 2014/0243254 A1 Hersel Et Al
- Global-Validated-Assay-List-April
- Methylphenidate Redistributes Vesicular Monoamine Transporter-2: Role of Dopamine Receptors
- PET Measurement of Cardiac and Nigrostriatal Denervation in Parkinsonian Syndromes
- AUSTEDO (Deutetrabenazine) Is a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for Oral Administration
- (12) Patent Application Publication (10) Pub. No.: US 2012/0003330 A1 Gant Et Al
- Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: an Update
- Monoaminergic PET Imaging and Histopathological Correlation In
- AUSTEDO (Deutetrabenazine) Tablets, for Oral Use Metabolizers Is 36 Mg Per Day (I.E., 18 Mg Twice Daily) (2.4, 8.7) Initial U.S
- Study Protocol
- Neuroimaging and Sleep Medicine * 睡眠呼吸障碍综合征 Eric A
- Deutetrabenazine for Tardive Dyskinesia
- [Product Monograph Template
- Drug Metabolite
- Imaging Approaches to Parkinson Disease
- Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: a Narrative Review
- Alcohol Use Disorder, Neurodegeneration, Alzheimer's and Parkinson's Disease